4.34
2.60%
+0.11
시간 외 거래:
4.34
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
GlobeNewswire Inc.
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
Benzinga
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Zacks Investment Research
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire Inc.
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Benzinga
Navigating 4 Analyst Ratings For Sutro Biopharma
Benzinga
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
GlobeNewswire Inc.
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Zacks Investment Research
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
GlobeNewswire Inc.
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
GlobeNewswire Inc.
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
GlobeNewswire Inc.
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
GlobeNewswire Inc.
Expert Ratings for Sutro Biopharma
Benzinga
자본화:
|
볼륨(24시간):